Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-U3334
Preterm Birth Prevention and Management Market Overview The rising necessity of preventing preterm births and increased emphasis on targeted therapies and care standards are some of the key factors contributing to the market growth. According to the data provided by the WHO, every year, over 15 million births are preterm. Complications arising from preterm births is the primary cause of mortality in children under the age of 5 with over 1 million deaths recorded in 2015. Over 70% of these deaths are preventable with cost-effective interventions. Due to these factors, it is estimated that the market shall propel during the forecast period. Treating progesterone during the pregnancy process shall help many women to be prevented from premature birth and a 17P shot is very effective in such cases. Vaginal progesterone and progesterone shots are two types of progesterone treatments. Vaginal progesterone helps in reducing premature birth in case the women is carrying one baby and has a shorter cervix. The progesterone shots help in reducing the risk of premature birth if the women previously had a premature birth. Such factors shall boost the preterm birth prevention and management market growth. Market Segmentation: By Therapy Type • Progesterone Therapy • Corticosteroid Therapy • Tocolytics Therapy • Antibiotics Therapy • Heparin Profylaxis Therapy • Others By Route of Administration • Oral • Parenteral • Vaginal By Distribution Channel • Drug Stores • Hospital Pharmacies • Mail Order Pharmacies • E-Pharmacies • Retail Pharmacies • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is fragmented into therapy type, route of administration, distribution channel and region. The therapy type segment is categorised into progesterone therapy, tocolytics therapy, corticosteroid therapy, antibiotics therapy, heparin profylaxis therapy and others. The route of administration segment is diversified into oral, vaginal and parenteral. The oral route is predicted to hold the largest preterm birth prevention and management market share during the forecast period. The distribution channel segment is bifurcated into hospital pharmacies, online pharmacies, drug stores. Regional Analysis: The North America region is predicted to lead the market during the forecast period owing to increased birth rates, rising awareness amongst women regarding preterm birth and major market players have their headquarters in the region. As per the Centers for Disease Control and Prevention, over 1 in every 10 infants were born premature in the US in the year 2018. Such statistics shall provide a boost to the market growth in the region. Competitive Landscape: The key players associated are AbbVie Inc., Allergan, AMAG Pharmaceuticals, Bayer AG, Ferring B.V., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Teva Pharmaceutical Industries Ltd. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global the preterm birth prevention and management market by therapy type, by route of administration, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The rising necessity of preventing preterm births and increased emphasis on targeted therapies and care standards are some of the key factors contributing to the market growth. According to the data provided by the WHO, every year, over 15 million births are preterm. Complications arising from preterm births is the primary cause of mortality in children under the age of 5 with over 1 million deaths recorded in 2015. Over 70% of these deaths are preventable with cost-effective interventions. Due to these factors, it is estimated that the market shall propel during the forecast period. Treating progesterone during the pregnancy process shall help many women to be prevented from premature birth and a 17P shot is very effective in such cases. Vaginal progesterone and progesterone shots are two types of progesterone treatments. Vaginal progesterone helps in reducing premature birth in case the women is carrying one baby and has a shorter cervix. The progesterone shots help in reducing the risk of premature birth if the women previously had a premature birth. Such factors shall boost the preterm birth prevention and management market growth.
Market Segmentation:
By Therapy Type • Progesterone Therapy • Corticosteroid Therapy • Tocolytics Therapy • Antibiotics Therapy • Heparin Profylaxis Therapy • Others
By Route of Administration • Oral • Parenteral • Vaginal
By Distribution Channel • Drug Stores • Hospital Pharmacies • Mail Order Pharmacies • E-Pharmacies • Retail Pharmacies • Others
By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is fragmented into therapy type, route of administration, distribution channel and region. The therapy type segment is categorised into progesterone therapy, tocolytics therapy, corticosteroid therapy, antibiotics therapy, heparin profylaxis therapy and others. The route of administration segment is diversified into oral, vaginal and parenteral. The oral route is predicted to hold the largest preterm birth prevention and management market share during the forecast period. The distribution channel segment is bifurcated into hospital pharmacies, online pharmacies, drug stores.
Regional Analysis:
The North America region is predicted to lead the market during the forecast period owing to increased birth rates, rising awareness amongst women regarding preterm birth and major market players have their headquarters in the region. As per the Centers for Disease Control and Prevention, over 1 in every 10 infants were born premature in the US in the year 2018. Such statistics shall provide a boost to the market growth in the region.
Competitive Landscape:
The key players associated are AbbVie Inc., Allergan, AMAG Pharmaceuticals, Bayer AG, Ferring B.V., Merck & Co. Inc., Mylan N.V., Pfizer Inc., Teva Pharmaceutical Industries Ltd.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global the preterm birth prevention and management market by therapy type, by route of administration, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Preterm Birth Prevention and Management Market, By Therapy Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 7.1 Progesterone Therapy 7.2 Corticosteroid Therapy 7.3 Tocolytics Therapy 7.4 Antibiotics Therapy 7.5 Heparin Profylaxis Therapy 7.6 Others 8. Preterm Birth Prevention and Management Market, By Route of Administration Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 8.1 Oral 8.2 Parenteral 8.3 Vaginal 9. Preterm Birth Prevention and Management Market, By Distribution Channel Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 9.1 Drug Stores 9.2 Hospital Pharmacies 9.3 Mail Order Pharmacies 9.4 E-Pharmacies 9.5 Retail Pharmacies 9.6 Others 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 14.2.1 GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 AbbVie Inc. 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Allergan 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 AMAG Pharmaceuticals 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 Bayer AG 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Ferring B.V. 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Merck & Co. Inc. 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Pfizer Inc. 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Mylan N.V. 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Teva Pharmaceutical Industries Ltd. 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix 18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies 19. Relevant Case Studies and Latest News Updates 20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders
2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study
3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights
4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances
5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges
6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape
7. Preterm Birth Prevention and Management Market, By Therapy Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 7.1 Progesterone Therapy 7.2 Corticosteroid Therapy 7.3 Tocolytics Therapy 7.4 Antibiotics Therapy 7.5 Heparin Profylaxis Therapy 7.6 Others
8. Preterm Birth Prevention and Management Market, By Route of Administration Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 8.1 Oral 8.2 Parenteral 8.3 Vaginal
9. Preterm Birth Prevention and Management Market, By Distribution Channel Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 9.1 Drug Stores 9.2 Hospital Pharmacies 9.3 Mail Order Pharmacies 9.4 E-Pharmacies 9.5 Retail Pharmacies 9.6 Others
10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020 10.2.1. U.S. 10.2.2. Canada 10.2.3. Mexico 10.2.4. Rest of North America 10.3 Market Size (USD Mn) Forecast for North America 2022-2028
11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Regional Market Trends 11.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 11.3.1. Brazil 11.3.2. Venezuela 11.3.3. Argentina 11.3.4. Rest of Latin America 11.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028
12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5 Switzerland 12.2.6. Spain 12.2.7. Russia 12.2.8. Poland 12.2.9. Rest of Western Europe 12.3 Market Size (US$ Mn) Forecast for Europe 2022-2028
13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1 Introduction 13.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 13.2.1 Japan 13.2.2 China 13.2.3 Singapore 13.2.4 Korea 13.2.5 India 13.2.6 Australia and New Zealand 13.2.7 ASEAN 13.2.8 Rest of Asia Pacific 13.3 Market Size (US$ Mn) Forecast for Asia Pacific 2022-2028
14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 14.2.1 GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3 Market Size (US$ Mn) Forecast for MEA 2022-2028
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 15.1 AbbVie Inc. 15.1.1. Company Overview (HQ, Business Segments, Employee Strength) 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2 Allergan 15.2.1. Company Overview (HQ, Business Segments, Employee Strength) 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3 AMAG Pharmaceuticals 15.3.1. Company Overview (HQ, Business Segments, Employee Strength) 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4 Bayer AG 15.4.1. Company Overview (HQ, Business Segments, Employee Strength) 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5 Ferring B.V. 15.5.1. Company Overview (HQ, Business Segments, Employee Strength) 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6 Merck & Co. Inc. 15.6.1. Company Overview (HQ, Business Segments, Employee Strength) 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7 Pfizer Inc. 15.7.1. Company Overview (HQ, Business Segments, Employee Strength) 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8 Mylan N.V. 15.8.1. Company Overview (HQ, Business Segments, Employee Strength) 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9 Teva Pharmaceutical Industries Ltd. 15.9.1. Company Overview (HQ, Business Segments, Employee Strength) 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview
16. Impact of COVID-19 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations
17. Competitive Intelligence and Competitive Matrix 17.1 Competitive Intelligence 17.2 Competitive Matrix
18. Major Deals and Strategic Alliances Analysis 18.1 Joint ventures 18.2 Mergers and acquisitions 18.3 Licensing and partnerships 18.4 Technology Collaborations 18.5 Strategic Divestments 18.6 Market Entry Strategies
19. Relevant Case Studies and Latest News Updates
20. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics